Lantern Pharma logo
Lantern Pharma
LTRN | NASDAQ
Chart Builder DCF Calculator
$0.46
-$0.14 (-23.21%)
At close: Nov 10, 2026, 4:00 PM ET

Lantern Pharma Company Profile

Company profile explained

Company Profile

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.

Key Executives

Name Position
Panna Sharma President, Chief Executive Officer & Director
David R. Margrave Chief Financial Officer & Secretary
Kishor Gopaldas Bhatia Chief Scientific Officer & Scientific Consultant
Marc C. Chamberlain Chief Medical Officer of Starlight Therapeutics
Peter L. Nara Co-Founder & Advisor

Latest SEC Filings

Date Type Title
Oct 21, 2026 ARS Filing
Oct 19, 2026 DEF 14A Filing
Oct 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 08, 2026 PRE 14A Filing
Oct 01, 2026 8-K Current Report
Sep 30, 2026 8-K Current Report
Sep 30, 2026 424B5 Filing
Sep 24, 2026 8-K Current Report
Sep 23, 2026 8-K Current Report
Aug 14, 2026 8-K Current Report
View All SEC Filings ➞
Lantern Pharma
Lantern Pharma logo
Country United States
IPO Date Jun 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Panna Sharma

Contact Details

1920 McKinney Avenue Dallas, Texas 75201 United States

Stock Details

Ticker Symbol LTRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001763950
CUSIP Number 51654W101
ISIN Number US51654W1018
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.